Anti-MERTK antibody [Y323]

Name	Anti-MERTK antibody [Y323]
Supplier	Abcam
Catalog	ab52968
Prices	$392.00
Sizes	100 µl
Host	Rabbit
Clonality	Monoclonal
Isotype	IgG
Clone	Y323
Applications	B/N WB IP IHC-P
Species Reactivities	Human
Antigen	Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human MERTK aa 1-100 (N terminal)
Description	Rabbit Monoclonal
Gene	MERTK
Conjugate	Unconjugated
Supplier Page	Shop

Product images

All lanes : Anti-MERTK antibody [Y323] (ab52968) at 1/2000 dilution (purified)Lane 1 : HEK293 cell lysateLane 2 : K562 cell lysateLysates/proteins at 20 µg per lane.SecondaryPeroxidase-conjugated goat anti-rabbit IgG at 1/1000 dilutionObserved band size : 140-180 kDa (why is the actual band size different from the predicted?)Blocking buffer and concentration: 5% NFDM/TBST.Diluting buffer and concentration: 5% NFDM /TBST.

Anti-MERTK antibody [Y323] (ab52968) at 1/1000 dilution (unpurified) + HEK293 cell lysate at 10 µgSecondaryHRP-conjugated goat anti-rabbit IgG at 1/2000 dilutionObserved band size : 180 kDa (why is the actual band size different from the predicted?)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labelling MERTK with purified ab52968 at 1/500. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human lymphoma tissue labelling MERTK with unpurified ab52968 at a 1/50 dilution.

ab52968 (purified) at 1/20 immunoprecipitating MERTK in HEK293 cell lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).Blocking buffer and concentration: 5% NFDM/TBST.Diluting buffer and concentration: 5% NFDM /TBST.

Product References

TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central - TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central

Pierce AM, Keating AK. Brain Res. 2014 Jan 13;1542:206-20.

Expansion of the CRISPR-Cas9 genome targeting space through the use of H1 - Expansion of the CRISPR-Cas9 genome targeting space through the use of H1

Ranganathan V, Wahlin K, Maruotti J, Zack DJ. Nat Commun. 2014 Aug 8;5:4516.

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential - Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential

Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, Deryckere D, Graham DK. Blood Cancer J. 2013 Jan 25;3:e101.

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in - Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in

Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, Keating AK, Earp HS, Liang X, DeRyckere D, Graham DK. Oncogene. 2013 Nov 14;32(46):5359-68.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma. - MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK. J Clin Invest. 2013 May;123(5):2257-67.

Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma - Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma

Wang Y, Moncayo G, Morin P Jr, Xue G, Grzmil M, Lino MM, Clement-Schatlo V, Frank S, Merlo A, Hemmings BA. Oncogene. 2013 Feb 14;32(7):872-82.

Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a - Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a

Migdall-Wilson J, Bates C, Schlegel J, Brandao L, Linger RM, DeRyckere D, Graham DK. PLoS One. 2012;7(2):e31635.

Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal - Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal

Deng WT, Dinculescu A, Li Q, Boye SL, Li J, Gorbatyuk MS, Pang J, Chiodo VA, Matthes MT, Yasumura D, Liu L, Alkuraya FS, Zhang K, Vollrath D, LaVail MM, Hauswirth WW. Invest Ophthalmol Vis Sci. 2012 Apr 6;53(4):1895-904.

Expansion of necrotic core and shedding of Mertk receptor in human carotid - Expansion of necrotic core and shedding of Mertk receptor in human carotid

Garbin U, Baggio E, Stranieri C, Pasini A, Manfro S, Mozzini C, Vallerio P, Lipari G, Merigo F, Guidi G, Cominacini L, Fratta Pasini A. Cardiovasc Res. 2013 Jan 1;97(1):125-33.

Molecular characterization and functional analysis of phagocytosis by human - Molecular characterization and functional analysis of phagocytosis by human

Carr AJ, Vugler A, Lawrence J, Chen LL, Ahmado A, Chen FK, Semo M, Gias C, da Cruz L, Moore HD, Walsh J, Coffey PJ. Mol Vis. 2009;15:283-95. Epub 2009 Feb 6.